Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI)

Main Article Content

April W. Armstrong
Mark Lebwohl
Jerry Bagel
Todd Schlesinger
Subhashis Banerjee
Renata M. Kisa
Thomas Scharnitz
Kim Hoyt
Bruce Strober


Deucravacitinib, psoriasis, tyrosine kinase 2, phase 3 clinical trial, efficacy, apremilast


1. Burke JR, et al. Sci Transl Med. 2019;11:eaaw1736.

2. Wrobleski ST et al. J Med Chem. 2019;62:8973-8995.

3. SOTYKTUTM (deucravacitinib) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; September 2022.

4. Armstrong AW, et al. J Am Acad Dermatol. 2023;88:29-39.

5. Strober B, et al. J Am Acad Dermatol. 2023;88:40-51.

6. Warren RB, et al. Presented at the EADV 30th Congress; September 29-October 2, 2021.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>